Lung Cancer ScreeningNCT07682597
Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based Initiative Component
A study testing QUILS SBI Intervention in people with Lung Cancer Screening, run by Timothy Mullett at 13 sites in United States.
Trial summary
This clinical trial studies whether a Quality Implementation of Lung Cancer Screening (QUILS™) System state-based initiative (SBI) intervention works to improve the statewide capacity for implementing and sustaining lung cancer screening in Mississippi (MS) and Nevada (NV). Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Lung Cancer Screening
- What is being tested?
- QUILS SBI Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 13 sitesUnited States
- Study dates
- 1 Mar 2026to 1 Jul 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Member of a state-based lung cancer screening implementation team in Mississippi or Nevada.
- Leadership member of the Mississippi state team or Nevada state team
- Active member of the Mississippi Lung Cancer Roundtable (MSLCRT) or Nevada Lung Cancer Coalition (NLCC)
- Willing to participate in study-related assessments an implementation activities
Who cannot join
- None
Trial locations and contacts
13 sites in 1 country. Contact the study team or a site near you to ask about taking part.
13 sites in 1 country
United States13 sites, 13 recruiting
- Recruiting
Delta Health System
Greenville, Mississippi, 38703
Joseph Alexander, 859-323-0892, joseph.alexander@uky.edu
- Recruiting
Greenwood Leflore Hospital
Greenwood, Mississippi, 38930
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Memorial Hospital Gulfport
Gulfport, Mississippi, 39501
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Hattiesburg Clinic
Hattiesburg, Mississippi, 39401
Joseph Alexander, 859-323-0892, joseph.alexander@uky.edu
- Recruiting
Mt. Grant General Hospital
Hawthorne, Nevada, 89415
Jospeh Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Baptist Memorial Hospital
New Albany, Mississippi, 38652
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Desert View Hospital
Pahrump, Nevada, 89048
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Renown Regional Medical Center
Reno, Nevada, 89502
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Sierra Medical Center
Reno, Nevada, 89511
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
North Mississippi Health Services
Tupelo, Mississippi, 38801
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Sunrise Health
Winchester, Nevada, 89109
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
- Recruiting
Humboldt General Hospital
Winnemucca, Nevada, 89445
Joseph Alexander, 8593230892, joseph.alexander@uky.edu
About this study
Official title: Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based
This clinical trial studies whether a Quality Implementation of Lung Cancer Screening (QUILS™) System state-based initiative (SBI) intervention works to improve the statewide capacity for implementing and sustaining lung cancer screening in Mississippi (MS) and Nevada (NV). The QUILS™ Group is focused on fair and high-quality implementation of lung cancer screening among eligible individuals to reduce lung cancer-related death in underserved communities. Previous research had success with implementing interventions in Kentucky which has lead to significant increases in lung cancer screening rates and a rapid decline in late-stage lung cancer diagnoses within the state. The goal is to offer the opportunity to replicate this work in states which are eager to address suboptimal screening rates, high lung cancer-related death, and significant health equity concerns. The QUILS™ SBI intervention involves translating the success of the initial work in Kentucky to impact lung cancer screening implementation and lung cancer outcomes in MS and NV through close collaboration with state-based partners. The QUILS™ SBI intervention may be an effective way to improve the statewide capacity for implementing and sustaining lung cancer screening in MS and NV.
- Conditions
- Lung Cancer Screening
- Being tested
- QUILS SBI Intervention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QUILS SBI InterventionBehavioural
Participants implement the QUILS™ SBI intervention over 4 years consisting of the following steps: 1) Hire and establish connections with both groups, work with the MSLCRT and NLCC during year 1; 2) Participate in annual meetings hosted by MSCLRT and NLCC during years 1-4; 3) Attend State Team Assessment Feedback Sessions during years 2-4; 4) Attend Coalition Assessment Feedback Sessions during years 2-4; 5) Prioritize objectives, identify areas to support, implementation of state-based initiative, and receive coaching/support during years 2 and 3; 6) Receive coaching and technical assistance to implement priority areas during years 1-4; 7) Participate in sustainability planning during year 4.
| Study group | Role | What they receive |
|---|---|---|
| Health Services Research (SBI Intervention) | Experimental | Participants implement the QUILS™ SBI intervention over 4 years consisting of the following steps: 1) Hire and establish connections with both groups, work with the MSLCRT and NLCC during year 1; 2) Participate in annual meetings hosted by MSCLRT and NLCC during years 1-4; 3) Attend State Team Assessment Feedback Sessions during years 2-4; 4) Attend Coalition Assessment Feedback Sessions during years 2-4; 5) Prioritize objectives, identify areas to support, implementation of state-based initiative, and receive coaching/support during years 2 and 3; 6) Receive coaching and technical assistance to implement priority areas during years 1-4; 7) Participate in sustainability planning during year 4. Receives: Behavioral: QUILS SBI Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Statewide Capacity Assessment Scores for Lung Cancer Screening Implementation and Sustainability Capacity
Statewide capacity will be assessed using the State Team Assessment (STA) and Coalition Assessment (CA) instruments. Higher scores indicate greater capacity to implement an sustain lung cancer screening activities.
Measured: Up to 3 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2026
- Study start1 Mar 2026
- Primary completion1 Jul 2028 (estimated)
- Study completion1 Jul 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer ScreeningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Timothy Mullett
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Timothy Mullett, University of Kentucky
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07682597
- Sponsor's protocol ID
- MCC-25-KYQUILS-NVMS
- Status last verified
- Jun 2026
- First submitted
- 26 Jun 2026
- Last updated
- 6 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based
- ClinicalTrials.gov ID
- NCT07682597
- Acronym / sponsor ID
- MCC-25-KYQUILS-NVMS
- Conditions
- Lung Cancer Screening
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Timothy MullettUniversity, hospital or other
- Study start
- 1 Mar 2026 (actual)
- Primary completion
- 1 Jul 2028 (estimated)
- Study completion
- 1 Jul 2029 (estimated)
- First posted
- 6 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial studies whether a Quality Implementation of Lung Cancer Screening (QUILS™) System state-based initiative (SBI) intervention works to improve the statewide capacity for implementing and sustaining lung cancer screening in Mississippi (MS) and Nevada (NV). The QUILS™ Group is focused on fair and high-quality implementation of lung cancer screening among eligible individuals to reduce lung cancer-related death in underserved communities. Previous research had success with implementing interventions in Kentucky which has lead to significant increases in lung cancer screening rates and a rapid decline in late-stage lung cancer diagnoses within the state. The goal is to offer the opportunity to replicate this work in states which are eager to address suboptimal screening rates, high lung cancer-related death, and significant health equity concerns. The QUILS™ SBI intervention involves translating the success of the initial work in Kentucky to impact lung cancer screening implementation and lung cancer outcomes in MS and NV through close collaboration with state-based partners. The QUILS™ SBI intervention may be an effective way to improve the statewide capacity for implementing and sustaining lung cancer screening in MS and NV.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Health Services Research (SBI Intervention) | Experimental | Behavioral: QUILS SBI InterventionParticipants implement the QUILS™ SBI intervention over 4 years consisting of the following steps: 1) Hire and establish connections with both groups, work with the MSLCRT and NLCC during year 1; 2) Participate in annual meetings hosted by MSCLRT and NLCC during years 1-4; 3) Attend State Team Assessment Feedback Sessions during years 2-4; 4) Attend Coalition Assessment Feedback Sessions during years 2-4; 5) Prioritize objectives, identify areas to support, implementation of state-based initiative, and receive coaching/support during years 2 and 3; 6) Receive coaching and technical assistance to implement priority areas during years 1-4; 7) Participate in sustainability planning during year 4. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Member of a state-based lung cancer screening implementation team in Mississippi or Nevada.
- Leadership member of the Mississippi state team or Nevada state team
- Active member of the Mississippi Lung Cancer Roundtable (MSLCRT) or Nevada Lung Cancer Coalition (NLCC)
- Willing to participate in study-related assessments an implementation activities
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QUILS SBI InterventionParticipants implement the QUILS™ SBI intervention over 4 years consisting of the following steps: 1) Hire and establish connections with both groups, work with the MSLCRT and NLCC during year 1; 2) Participate in annual meetings hosted by MSCLRT and NLCC during years 1-4; 3) Attend State Team Assessment Feedback Sessions during years 2-4; 4) Attend Coalition Assessment Feedback Sessions during years 2-4; 5) Prioritize objectives, identify areas to support, implementation of state-based initiative, and receive coaching/support during years 2 and 3; 6) Receive coaching and technical assistance to implement priority areas during years 1-4; 7) Participate in sustainability planning during year 4. | Behavioural | Health Services Research (SBI Intervention) |
Primary outcome
Change in Statewide Capacity Assessment Scores for Lung Cancer Screening Implementation and Sustainability Capacity
Time frame: Up to 3 Years
Statewide capacity will be assessed using the State Team Assessment (STA) and Coalition Assessment (CA) instruments. Higher scores indicate greater capacity to implement an sustain lung cancer screening activities.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2026.
Related trials for Lung Cancer Screening
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
Active, not recruitingObservational study
Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial
Cancer, Death
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
13 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing QUILS SBI Intervention in people with Lung Cancer Screening, run by Timothy Mullett at 13 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 13 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joseph Alexander, MD (8593230892, joseph.alexander@uky.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Statewide Capacity Assessment Scores for Lung Cancer Screening Implementation and Sustainability Capacity (time frame: Up to 3 Years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.